&PARTNERS Buys 34,537 Shares of Amgen Inc. $AMGN

&PARTNERS boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 14.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 279,569 shares of the medical research company’s stock after acquiring an additional 34,537 shares during the period. &PARTNERS’s holdings in Amgen were worth $91,583,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Anfield Capital Management LLC grew its position in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC lifted its position in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Amgen in the fourth quarter worth about $26,000. Manning & Napier Advisors LLC boosted its stake in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC purchased a new position in Amgen during the 4th quarter valued at approximately $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. UBS Group lifted their price objective on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Sunday. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a research report on Friday, June 5th. Guggenheim decreased their price target on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research note on Monday, May 4th. Finally, Daiwa Securities Group lowered their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $354.42.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $347.84 on Wednesday. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm has a 50-day moving average price of $341.02 and a 200-day moving average price of $345.89. The firm has a market capitalization of $187.73 billion, a PE ratio of 24.21, a price-to-earnings-growth ratio of 3.52 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 22.38 EPS for the current year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.